晚期黑色素瘤的治疗：过去、现在与未来
Treatment of Advanced Melanoma: Past, Present and Future.
作者信息
Fujimura Taku, Kambayashi Yumi, Ohuchi Kentaro, Muto Yusuke, Aiba Setsuya
机构信息
Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
出版信息
Life (Basel). 2020 Sep 16;10(9):208. doi: 10.3390/life10090208.
Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.
治疗晚期黑色素瘤的治疗选择正在迅速发展。直到六年前，治疗晚期黑色素瘤的方案主要包括细胞毒性药物如达卡巴嗪和I型干扰素。自2014年以来，抗程序性细胞死亡1（PD1）抗体已被公认为治疗晚期黑色素瘤的基础药物，无论是否联合使用如伊匹单抗等其他联合药物。此外，v-Raf鼠肉瘤病毒癌基因同源物B1（BRAF）激酶抑制剂与丝裂原活化蛋白激酶激酶（MEK）抑制剂联合使用是治疗晚期BRAF突变黑色素瘤最有前景的化疗方案之一，尤其是对于肿瘤负荷低的患者。由于抗PD1抗体广泛适用于野生型和突变型晚期黑色素瘤的治疗，目前正在进行多项与抗PD1抗体联合用药的临床试验。本综述重点关注当今可用的抗黑色素瘤疗法的发展，并讨论治疗晚期黑色素瘤新方案的临床试验。
Zotero 插件